Zinthoma, Antiretroviral and Nausea and Vomiting

Evaluation of zinthoma efficacy in prevention of antiretrovirals nausea and vomiting in HIV positive patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT201305283449N12

Enrollment

Registered

2013-06-17

Start date

2011-02-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV/AIDS. Human immunodeficiency virus [HIV] disease

Interventions

Intervention 1: Intervention (Drug): Zinthoma 2 Cap (500 mg)30 minutes before each dose of antiretroviral twice daily for 14 days. Intervention 2: Control: Placebo 2 Cap ( 500 mg) 30 minutes before ea

Treatment - Drugs

Placebo

Intervention (Drug): Zinthoma 2 Cap (500 mg)30 minutes before each dose of antiretroviral twice daily for 14 days

Control: Placebo 2 Cap ( 500 mg) 30 minutes before each dose of antiretroviral twice daily for 14 days

Eligibility

Sex/Gender

All

Age

16 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: HIV positive patients who are candidate for Antiretroviral therapy and who signe study consent form. Exclusion criteria: History of zinthoma or othera herbal products hypersensitivity

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Frequency of Nausea and Vomoting. Timepoint: During 2 weeks of starting antiretroviral. Method of measurement: Visual analouge scale.	—

Secondary

Measure	Time frame
Severity of nausea. Timepoint: Dring 2 weeks of starting antiretroviral. Method of measurement: Visual analogue scale.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026